Literature DB >> 17533370

The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells.

A Sirvent1, A Boureux, V Simon, C Leroy, S Roche.   

Abstract

The cytoplasmic tyrosine kinase Src has been implicated in signal transduction induced by growth factors and integrins. Src also shows oncogenic activity when deregulated. Accumulating evidence indicates that the tyrosine kinase Abl is an important substrate for Src signalling in normal cells. Here we show that Abl is also required for Src-induced transformation of mouse fibroblasts. Abl does not mediate tyrosine phosphorylation of Stat3 and Shc, two important regulators of Src oncogenic activity. In contrast, Abl controls the activation of the small GTPase Rac for oncogenic signalling and active Rac partly rescued Src transformation in cells with inactive Abl. Moreover, Abl mediates Src-induced extracellular regulated kinase 5 (ERK5) activation to drive cell transformation. Finally, we find that Abl/Rac and Abl/ERK5 pathways also operate in human MCF7 and BT549 breast cancer cells, where neoplastic transformation depends on Src-like activities. Therefore, Abl is an important regulator of Src oncogenic activity both in mouse fibroblasts and in human cancer cells. Targeting these Abl-dependent signalling cascades may be of therapeutic value in breast cancers where Src-like function is important.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533370     DOI: 10.1038/sj.onc.1210543

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  Abl regulates smooth muscle cell proliferation by modulating actin dynamics and ERK1/2 activation.

Authors:  Li Jia; Ruping Wang; Dale D Tang
Journal:  Am J Physiol Cell Physiol       Date:  2012-02-01       Impact factor: 4.249

2.  N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor.

Authors:  Yongmun Choi; Markus A Seeliger; Shoghag B Panjarian; Hakjoong Kim; Xianming Deng; Taebo Sim; Brian Couch; Anthony J Koleske; Thomas E Smithgall; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-08-13       Impact factor: 5.157

Review 3.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

Review 4.  Targeting key transcriptional factor STAT3 in colorectal cancer.

Authors:  Gayathri Chalikonda; Hoomin Lee; Aliya Sheik; Yun Suk Huh
Journal:  Mol Cell Biochem       Date:  2021-04-18       Impact factor: 3.396

Review 5.  The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells.

Authors:  Tressa M Allington; William P Schiemann
Journal:  Cells Tissues Organs       Date:  2010-11-03       Impact factor: 2.481

6.  Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts.

Authors:  Audrey Sirvent; Oana Vigy; Beatrice Orsetti; Serge Urbach; Serge Roche
Journal:  Mol Cell Proteomics       Date:  2012-09-29       Impact factor: 5.911

7.  Activation of abl family kinases in solid tumors.

Authors:  Sourik S Ganguly; Rina Plattner
Journal:  Genes Cancer       Date:  2012-05

8.  c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration.

Authors:  Anna Baruzzi; Ilaria Iacobucci; Simona Soverini; Clifford A Lowell; Giovanni Martinelli; Giorgio Berton
Journal:  FEBS Lett       Date:  2010-01-04       Impact factor: 4.124

9.  Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors.

Authors:  Tressa M Allington; Amy J Galliher-Beckley; William P Schiemann
Journal:  FASEB J       Date:  2009-08-18       Impact factor: 5.191

10.  Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.

Authors:  Annabell S Oh; John T Lahusen; Christopher D Chien; Mark P Fereshteh; Xiaolong Zhang; Sivanesan Dakshanamurthy; Jianming Xu; Benjamin L Kagan; Anton Wellstein; Anna T Riegel
Journal:  Mol Cell Biol       Date:  2008-09-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.